Table 4 Studies of stereotactic body radiotherapy for stage I non-small cell lung cancer
Author | Â | Dose* median follow-up | 3yLC | 3yOS | |
|---|---|---|---|---|---|
(reference) | n | (Gy) | (mo) | (%) | (%) |
Onishi (2) | 257 | 30-84(i) | 38 | NA | 57 |
Timmerman (8) | 55 | 54(p) | 34 | 98 | 56 |
Nagata (10) | 42 | 48(i) | 30 | NA | 83 (T1 only) |
Onimaru (21) | 41 | 40-48(i) | 27 | 57 | 47 |
Uematsu (30) | 50 | 40-60(i) | 60 | NA | 66 |
Koto (31) | 31 | 45-60(i) | 32 | 78 | 72 |
Nyman (32) | 45 | 45(p) | 43 | 80 | 55 |
Takeda (33) | 38 | 50(p) | 31 | 93 (T1 only) | 90 (T1 only) |
Taremi (34) | 108 | 48-60(p) | 19 | 89 (4y) | 30 (4y) |
Current study | 109 | 48(i) or 40(p) | 25 | 81 | 68 |